Rigel Pharma scores FDA approval for leukemia, kicking off showdown with Servier in IDH1

Amber Tong

When Rigel Pharma bought olutasidenib from Forma Therapeutics, it acquired a drug that already secured a PDUFA date at the FDA — for February 2023. But …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Rigel Pharma scores FDA approval for leukemia, kicking off showdown with Servier in IDH1

Amber Tong

Sign up to read this article for free.

J&J, Protagonist reveal two Phase 3 wins for oral IL-23 drug that's expected to be a blockbuster

Former NCI director teams up with serial entrepreneur for $70M VC fund targeting 'super-early' science

Merck finally has subcutaneous Keytruda results, and it's going to regulators

Biogen, UCB detail response rates in Phase 3 lupus trial after surprising success

Bristol Myers takes on autoimmune diseases with cell therapy, plus new data from Cabaletta and Kyverna

Are programs with compounded GLP-1s safe for your population?

Rigel Phar­ma scores FDA ap­proval for leukemia, kick­ing off show­down with Servi­er in IDH1

Amber Tong

Sign up to read this article for free.

J&J, Pro­tag­o­nist re­veal two Phase 3 wins for oral IL-23 drug that's ex­pect­ed to be a block­buster

For­mer NCI di­rec­tor teams up with se­r­i­al en­tre­pre­neur for $70M VC fund tar­get­ing 'su­per-ear­ly' sci­ence

Mer­ck fi­nal­ly has sub­cu­ta­neous Keytru­da re­sults, and it's go­ing to reg­u­la­tors

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

Bris­tol My­ers takes on au­toim­mune dis­eases with cell ther­a­py, plus new da­ta from Ca­balet­ta and Kyver­na

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Rigel Pharma scores FDA approval for leukemia, kicking off showdown with Servier in IDH1

J&J, Protagonist reveal two Phase 3 wins for oral IL-23 drug that's expected to be a blockbuster

Former NCI director teams up with serial entrepreneur for $70M VC fund targeting 'super-early' science

Merck finally has subcutaneous Keytruda results, and it's going to regulators

Biogen, UCB detail response rates in Phase 3 lupus trial after surprising success

Bristol Myers takes on autoimmune diseases with cell therapy, plus new data from Cabaletta and Kyverna

Are programs with compounded GLP-1s safe for your population?